Sign up to save your podcasts
Or
Share Creating Personalized Care in Relapsed/Refractory Follicular Lymphoma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Creating Personalized Care in Relapsed/Refractory Follicular Lymphoma
CME credits: 0.25
Valid until: 19-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/creating-personalized-care-relapsedrefractory-follicular-lymphoma/12578/
The epigenetic modulator EZH2 is known to play a crucial role in mediating the lymphomagenesis of follicular lymphoma (FL), and the inhibition of EZH2 in the relapsing/refractory disease setting has shown efficacy. In this activity, Drs. Matasar and Nastoupil discuss the role of EZH2 in the pathobiology of FL, emphasize the need to test for mutations in EZH2 in FL, and explore the potential of targeting EZH2 in different settings of FL treatment.
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 19-05-2022
Claim your CME credit at https://reachmd.com/programs/cme/creating-personalized-care-relapsedrefractory-follicular-lymphoma/12578/
The epigenetic modulator EZH2 is known to play a crucial role in mediating the lymphomagenesis of follicular lymphoma (FL), and the inhibition of EZH2 in the relapsing/refractory disease setting has shown efficacy. In this activity, Drs. Matasar and Nastoupil discuss the role of EZH2 in the pathobiology of FL, emphasize the need to test for mutations in EZH2 in FL, and explore the potential of targeting EZH2 in different settings of FL treatment.